TY - JOUR
T1 - Identification of host–pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank
AU - Mentzer, Alexander J.
AU - Brenner, Nicole
AU - Allen, Naomi
AU - Littlejohns, Thomas J.
AU - Chong, Amanda Y.
AU - Cortes, Adrian
AU - Almond, Rachael
AU - Hill, Michael
AU - Sheard, Simon
AU - McVean, Gil
AU - Aiello, Allison
AU - Bangham, Charles
AU - Borrow, Ray
AU - Breuer, Judy
AU - Brooks, Tim
AU - Franceschi, Silvia
AU - Gkrania-Klotsas, Effrossyni
AU - Greenwood, Brian
AU - Griffiths, Paul
AU - Guy, Edward
AU - Jeffery, Katie
AU - Kelly, Dominic
AU - Klenerman, Paul
AU - van der Klis, Fiona
AU - Knight, Julian
AU - McMichael, Andrew
AU - Naranbhai, Vivek
AU - Pebody, Richard
AU - Peto, Tim
AU - Pollard, Andrew J.
AU - Schulz, Thomas
AU - Soldan, Kate
AU - Taylor, Graham
AU - Towers, Greg
AU - Tommasino, Massimo
AU - Weiss, Robin
AU - Whitby, Denise
AU - Wild, Chris
AU - Wyllie, David
AU - UKB Infection Advisory Board
AU - Collins, Rory
AU - Hill, Adrian V.S.
AU - Waterboer, Tim
N1 - Funding Information:
AJM was supported by a Wellcome Trust Fellowship with reference 106289/Z/14/Z and by an Oxford University Clinical Academic Graduate School Transitional Fellowship and by the National Institute of Health Research. The research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. The work of T.W. was supported by the Dieter Morszeck Foundation. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4/5
Y1 - 2022/4/5
N2 - Certain infectious agents are recognised causes of cancer and other chronic diseases. To understand the pathological mechanisms underlying such relationships, here we design a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 infectious agents including human herpes, hepatitis, polyoma, papilloma, and retroviruses, as well as Chlamydia trachomatis, Helicobacter pylori and Toxoplasma gondii, then assayed a random subset of 9695 UK Biobank participants. We find seroprevalence estimates consistent with those expected from prior literature and confirm multiple associations of antibody responses with sociodemographic characteristics (e.g., lifetime sexual partners with C. trachomatis), HLA genetic variants (rs6927022 with Epstein-Barr virus (EBV) EBNA1 antibodies) and disease outcomes (human papillomavirus-16 seropositivity with cervical intraepithelial neoplasia, and EBV responses with multiple sclerosis). Our accessible dataset is one of the largest incorporating diverse infectious agents in a prospective UK cohort offering opportunities to improve our understanding of host-pathogen-disease relationships with significant clinical and public health implications.
AB - Certain infectious agents are recognised causes of cancer and other chronic diseases. To understand the pathological mechanisms underlying such relationships, here we design a Multiplex Serology platform to measure quantitative antibody responses against 45 antigens from 20 infectious agents including human herpes, hepatitis, polyoma, papilloma, and retroviruses, as well as Chlamydia trachomatis, Helicobacter pylori and Toxoplasma gondii, then assayed a random subset of 9695 UK Biobank participants. We find seroprevalence estimates consistent with those expected from prior literature and confirm multiple associations of antibody responses with sociodemographic characteristics (e.g., lifetime sexual partners with C. trachomatis), HLA genetic variants (rs6927022 with Epstein-Barr virus (EBV) EBNA1 antibodies) and disease outcomes (human papillomavirus-16 seropositivity with cervical intraepithelial neoplasia, and EBV responses with multiple sclerosis). Our accessible dataset is one of the largest incorporating diverse infectious agents in a prospective UK cohort offering opportunities to improve our understanding of host-pathogen-disease relationships with significant clinical and public health implications.
UR - http://www.scopus.com/inward/record.url?scp=85127748001&partnerID=8YFLogxK
U2 - 10.1038/s41467-022-29307-3
DO - 10.1038/s41467-022-29307-3
M3 - Article
C2 - 35383168
AN - SCOPUS:85127748001
SN - 2041-1723
VL - 13
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 1818
ER -
